You are subscribed to the Ophthalmology Times Issue Alert.

Ophthalmology Times Issue Alert

eNewsletter Subscribe

Print Subscribe

Digital Edition Subscribe

August 13, 2014

Web Version  |  Share with a colleague  |  View Digital Edition

Facebook Like   Twitter Tweet

CHECK OUT OUR AUGUST ISSUE

Stargardt's disease: New strategies, new therapies

Examining various methods and treatments currently in clinical and pre-clinical stages. » Read the research

The history of symbols, signs in medicine

Deciphering the symbols, signs, and abbreviations used every day in medical records, which have ancient roots in history.
» Read the history

VISTA, VIVID: Aflibercept effective DME therapy

Global phase III study's data shows durable visual acuity gains through 2 years, may provide even further insight.
» Read the results

ROCK/NET inhibitor, latanoprost meet endpoint

Fixed-dose combination achieved its primary endpoint, showing potential as a high-efficacy, IOP-lowering therapy in a phase IIb trial. » Click for results

Glaucoma care strategies in developing countries

SLT has been found to provide a majority of Afri-Caribbean patients with IOP reduction with no need for medical therapy.
» Find out how

Surgery advances = higher patient expectations?

Samuel Masket, MD, challenges young U.S. physicians to further the state of anterior segment eye surgery. » Read the article

Related Articles

Stargardt's disease treatment gains orphan designation

Two-stage, well-tolerated procedure for inlay ensures refractive stability

Quiz: Who is this medical truant?

Aflibercept acuity gains rival laser for BRVO

 

Downloads

Ophthalmology Times App - Download Ophthalmology Times Digital Edition - Download

You are subscribed to the Ophthalmology Times Issue Alert.

 
Powered by Modern Medicine Advanstar Medical Communications Group